DrugPatentWatch Database Preview
Deflazacort - Generic Drug Details
What are the generic sources for deflazacort and what is the scope of patent protection?
Deflazacort
is the generic ingredient in one branded drug marketed by Ptc Therap and is included in two NDAs. Additional information is available in the individual branded drug profile pages.There are three drug master file entries for deflazacort. One supplier is listed for this compound.
Summary for deflazacort
| US Patents: | 0 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 2 |
| Drug Master File Entries: | 3 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 62 |
| Clinical Trials: | 23 |
| Patent Applications: | 7,141 |
| What excipients (inactive ingredients) are in deflazacort? | deflazacort excipients list |
| DailyMed Link: | deflazacort at DailyMed |
Recent Clinical Trials for deflazacort
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Parc de Salut Mar | Phase 1 |
| FibroGen | Phase 3 |
| Catabasis Pharmaceuticals | Phase 1 |
Pharmacology for deflazacort
| Drug Class | Corticosteroid |
| Mechanism of Action | Corticosteroid Hormone Receptor Agonists |
US Patents and Regulatory Information for deflazacort
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ptc Therap | EMFLAZA | deflazacort | TABLET;ORAL | 208684-003 | Feb 9, 2017 | RX | Yes | No | ⤷ Free Forever Trial | ⤷ Free Forever Trial | ⤷ Free Forever Trial | ||||
| Ptc Therap | EMFLAZA | deflazacort | TABLET;ORAL | 208684-004 | Feb 9, 2017 | RX | Yes | Yes | ⤷ Free Forever Trial | ⤷ Free Forever Trial | ⤷ Free Forever Trial | ||||
| Ptc Therap | EMFLAZA | deflazacort | SUSPENSION;ORAL | 208685-001 | Feb 9, 2017 | RX | Yes | Yes | ⤷ Free Forever Trial | ⤷ Free Forever Trial | ⤷ Free Forever Trial | ||||
| Ptc Therap | EMFLAZA | deflazacort | TABLET;ORAL | 208684-001 | Feb 9, 2017 | RX | Yes | No | ⤷ Free Forever Trial | ⤷ Free Forever Trial | ⤷ Free Forever Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2021 - 2022
NCE-1 Patent Challenge Dates 2021 - 2022
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2021, www.DrugPatentWatch.com.
Follow DrugPatentWatch:
